fbpx

Weekly Top News – Psoriasis – November 25, 2019

November 25, 2019

Otezla (apremilast) / Amgen
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) – Nov 25, 2019 – P3b; N=140; Not yet recruiting; Sponsor: Celgene

 

BMS-986165 / BMS
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea (clinicaltrials.gov) – Nov 18, 2019 – P3; N=180; Not yet recruiting; Sponsor: Bristol-Myers Squibb

 

Otezla (apremilast) / Amgen
Amgen completes acquisition of Otezla (apremilast) (PRNewswire) – Nov 21, 2019 – “Amgen…today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast)…for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation…in connection with its previously announced merger with Bristol-Myers Squibb Company…which was completed on Nov. 20….With the closing of the Otezla acquisition, the Company is updating its overall 2019 guidance. For the full year 2019, the Company now expects total revenues in the range of $23.1 billion to $23.3 billion.”

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi WW sales projection: Guidance of $275M (previously $250M) in 2019 (Zacks) – Nov 21, 2019 – A subscription to Thomson ONE is required to gain full access to report 68317955; Page no: 5; REPORT TITLE: “AbbVie Inc.(ABBV) Zacks company report”; AUTHOR: Research Department; DATE: 11/11/2019

 

AK101 / Akesobio
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) – Nov 22, 2019 – P2b; N=280; Not yet recruiting; Sponsor: Akeso

 

Cosentyx (secukinumab) / Novartis
Cosentyx TRx trend: +26% q/q till date in Q4 2019 (J.P. Morgan) – Nov 22, 2019 – A subscription to Thomson ONE is required to gain full access to report 68355767; Page no: 1; REPORT TITLE: “Pharmaceuticals weekly: Weekly chartbook: TRx for week ending November 8th.”; AUTHOR: Vosser, Richard, et al; DATE: 11/15/2019

 

PF-06763809 / Pfizer
Further clarification regarding the ROR-gamma project (Yahoo Finance) – Nov 20, 2019 – “The development project, PF-06763809, was run internally by Pfizer….There has been no involvement from Karo Pharma in the project nor the decision to terminate was made by Pfizer at Pfizer’s sole discretion….Karo Pharma communicated theoretical milestones of up to 200 MUSD related to the Pfizer agreement. These potential milestone payments were all related to the specific project, PF-06763809. Given the termination of PF-06763809, none of these milestone payments will materialize.”

 

Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko Kirin
LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis (clinicaltrials.gov) – Nov 21, 2019 – P=N/A; N=3500; Enrolling by invitation; Sponsor: Bausch Health Americas, Inc.; Not yet recruiting –> Enrolling by invitation

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
AbbVie’s new launches Skyrizi, Rinvoq aren’t getting enough credit: Analyst (Fierce Pharma) – Nov 22, 2019 – “Psoriasis med Skyrizi and rheumatoid arthritis therapy Rinvoq could hit $11 billion in peak sales with scripts on the way up and market access growing…Combined with the highly successful launch of Rinvoq, AbbVie could see sales of both drugs top $1 billion next year––significantly higher than consensus estimates of around $800 million….Industry watchers expect Rinvoq to hit 75% access in January 2020, way ahead of UBS’ previous estimate…”

 

Otezla (apremilast) / Amgen
DARWIN: A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice (clinicaltrials.gov) – Nov 19, 2019 – P=N/A; N=375; Recruiting; Sponsor: Celgene; Not yet recruiting –> Recruiting

No Comments

Post a Comment

Comment
Name
Email
Website